Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties
Antibody drugs should exhibit not only high-binding affinity for their target antigens but also favorable physicochemical drug-like properties. Such drug-like biophysical properties are essential for the successful development of antibody drug products. The traditional approaches used in antibody dr...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | mAbs |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2022.2164459 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849467948371017728 |
|---|---|
| author | Hristo L. Svilenov Paolo Arosio Tim Menzen Peter Tessier Pietro Sormanni |
| author_facet | Hristo L. Svilenov Paolo Arosio Tim Menzen Peter Tessier Pietro Sormanni |
| author_sort | Hristo L. Svilenov |
| collection | DOAJ |
| description | Antibody drugs should exhibit not only high-binding affinity for their target antigens but also favorable physicochemical drug-like properties. Such drug-like biophysical properties are essential for the successful development of antibody drug products. The traditional approaches used in antibody drug development require significant experimentation to produce, optimize, and characterize many candidates. Therefore, it is attractive to integrate new methods that can optimize the process of selecting antibodies with both desired target-binding and drug-like biophysical properties. Here, we summarize a selection of techniques that can complement the conventional toolbox used to de-risk antibody drug development. These techniques can be integrated at different stages of the antibody development process to reduce the frequency of physicochemical liabilities in antibody libraries during initial discovery and to co-optimize multiple antibody features during early-stage antibody engineering and affinity maturation. Moreover, we highlight biophysical and computational approaches that can be used to predict physical degradation pathways relevant for long-term storage and in-use stability to reduce the need for extensive experimentation. |
| format | Article |
| id | doaj-art-375ca2578f7d4343a49f80dafa044d39 |
| institution | Kabale University |
| issn | 1942-0862 1942-0870 |
| language | English |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | mAbs |
| spelling | doaj-art-375ca2578f7d4343a49f80dafa044d392025-08-20T03:25:59ZengTaylor & Francis GroupmAbs1942-08621942-08702023-12-0115110.1080/19420862.2022.2164459Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical propertiesHristo L. Svilenov0Paolo Arosio1Tim Menzen2Peter Tessier3Pietro Sormanni4Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Gent, BelgiumDepartment of Chemistry and Applied Biosciences, ETH Zürich, Zürich, SwitzerlandCoriolis Pharma Research GmbH, Martinsried, 82152, GermanyDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USACentre for Misfolding Diseases, Yusuf Hamied Department of Chemistry, University of Cambridge, Cambridge, UKAntibody drugs should exhibit not only high-binding affinity for their target antigens but also favorable physicochemical drug-like properties. Such drug-like biophysical properties are essential for the successful development of antibody drug products. The traditional approaches used in antibody drug development require significant experimentation to produce, optimize, and characterize many candidates. Therefore, it is attractive to integrate new methods that can optimize the process of selecting antibodies with both desired target-binding and drug-like biophysical properties. Here, we summarize a selection of techniques that can complement the conventional toolbox used to de-risk antibody drug development. These techniques can be integrated at different stages of the antibody development process to reduce the frequency of physicochemical liabilities in antibody libraries during initial discovery and to co-optimize multiple antibody features during early-stage antibody engineering and affinity maturation. Moreover, we highlight biophysical and computational approaches that can be used to predict physical degradation pathways relevant for long-term storage and in-use stability to reduce the need for extensive experimentation.https://www.tandfonline.com/doi/10.1080/19420862.2022.2164459AntibodiesmAbsdevelopabilitymanufacturabilitydrug-like propertiesearly-stage screening |
| spellingShingle | Hristo L. Svilenov Paolo Arosio Tim Menzen Peter Tessier Pietro Sormanni Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties mAbs Antibodies mAbs developability manufacturability drug-like properties early-stage screening |
| title | Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties |
| title_full | Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties |
| title_fullStr | Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties |
| title_full_unstemmed | Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties |
| title_short | Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties |
| title_sort | approaches to expand the conventional toolbox for discovery and selection of antibodies with drug like physicochemical properties |
| topic | Antibodies mAbs developability manufacturability drug-like properties early-stage screening |
| url | https://www.tandfonline.com/doi/10.1080/19420862.2022.2164459 |
| work_keys_str_mv | AT hristolsvilenov approachestoexpandtheconventionaltoolboxfordiscoveryandselectionofantibodieswithdruglikephysicochemicalproperties AT paoloarosio approachestoexpandtheconventionaltoolboxfordiscoveryandselectionofantibodieswithdruglikephysicochemicalproperties AT timmenzen approachestoexpandtheconventionaltoolboxfordiscoveryandselectionofantibodieswithdruglikephysicochemicalproperties AT petertessier approachestoexpandtheconventionaltoolboxfordiscoveryandselectionofantibodieswithdruglikephysicochemicalproperties AT pietrosormanni approachestoexpandtheconventionaltoolboxfordiscoveryandselectionofantibodieswithdruglikephysicochemicalproperties |